Synergistic Regeneration of Osteoporotic Bone Defects Using PBM, Stem Cells, and hMPMS Scaffolds Via the miR-21/RUNX2 Axis.
Fallah B., Amini A., Mostafavinia A., Asgharnejad P., Mahdavi M., Moteshakereh SM.
Animal Study with a reported sample of 6, published in Cell Biochem Biophys (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Cell Biochem Biophys (2025)
- Country
- United States
- Reported sample size
- 6
- Source database
- PubMed
- PMID
- 41251957
- DOI
- 10.1007/s12013-025-01948-3
Abstract (original English)
Postmenopausal osteoporosis compromises bone regeneration and elevates the risk of fracture nonunion, underscoring the necessity for more effective regenerative strategies. In this study, we investigated the regenerative efficacy of a combined therapy consisting of photobiomodulation (PBM), preconditioned adipose-derived stem cells (ADSCs), and human decellularized and mineralized placental matrix scaffolds (hDMPMS), in an ovariectomized induced osteoporosis (OVX) rat with critical-sized femoral defects (CSFD). We surgically created critical-size femoral defects (CSFD) in the distal metaphysis of the left and right femurs of thirty OVX rats. After inducing CSFD, hDMPMSs were implanted into each defect site. The animals were then randomly divided into five groups (n = 6 each group): (1) Control, (2) Scaffold, (3) Scaffold + Cell, (4) Scaffold + PBM (810 nm, 1.2 J/cm²), and (5) Scaffold + Cell + PBM. Eight weeks after treatment, the defect sites in the left femoral bone were harvested and subjected to mechanical compression testing, bone density measurement, as well as gene expression and histological analyses. One-way ANOVA revealed significant (P < 0.001) improvements in biomechanical strength, histological parameters, and bone density in all treatment groups compared to the control group. Among them, the combination treatment group (Cell + PBM) demonstrated the greatest enh
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.